NZ: post-election, GM hangs in the balance
02 August, 2002 by Tanya HollisThe post-election future of genetic modification in New Zealand hangs in the balance with the Labour Party still to determine the structure of its government.
BioStart money confirmed for Mimetica
01 August, 2002 by Pete YoungBrisbane drug design company Mimetica is the first recipient of funds from Queensland's $6 million BioStart pre-seed fund, as foreshadowed by Australian Biotechnology News in June.
von Itzstein named as Federation Fellowship winner
01 August, 2002 by Pete YoungOnly one biotech luminary, drug discovery researcher Prof Mark von Itzstein, made the list the list of 11 Federation Fellowship winners announced this week by Health Minister Brendan Nelson.
BresaGen claims stem cell breakthrough
01 August, 2002 by Melissa TrudingerAdelaide-based company BresaGen has claimed a stem cell breakthrough, announcing that the company had successfully derived neural precursor cells from human embryonic stem cell lines.
Cryosite profit aims ahead of target
01 August, 2002 by Iain ScottPrivate cord blood storage service Cryosite has said it now does not expect to have to go through another round of fund-raising to achieve profitability.
Cochlear regains ground
31 July, 2002 by Tanya HollisHomegrown bionic ear maker Cochlear continued to rally investor support today on the back of news its US rival Advanced Bionics had withdrawn its device from sale.
Industry Minister lets the Sunshine in
31 July, 2002 by Iain ScottIndustry Minister Ian Macfarlane was on hand to open the doors on a new research facility for devices company Sunshine Heart in Sydney today.
Genesis announces loss, but ample cash reserves
30 July, 2002 by Tanya HollisNew Zealand genomics company Genesis Research and Development Corporation has delivered a half-year loss of $NZ5.3 million ($4.57 million), but maintained sufficient cash reserves to support planned research programs.
BresaGen to shed nine jobs in wake of failed partnership
30 July, 2002 by Tanya HollisAdelaide-based biotechnology company BresaGen has announced nine redundancies and a hiring freeze in the wake of the failed E21R collaboration with British Biotech.
Cerylid claims 95 per cent success rate in early screening
29 July, 2002 by Tanya HollisGenomics-based drug discovery company Cerylid Biosciences has announced that its lead anti-cancer compound successfully halted the disease in 95 per cent of human cell lines used.
Eiffel gains control of R&D arm
29 July, 2002 by Tanya HollisEiffel Technologies has gained full control of its research and development arm in a move that will ensure all future revenue streams flow directly to the drug reformulation company.
Market over-reacting to cochlear fears: analysts
29 July, 2002 by Tanya HollisA warning on meningitis risk by US cochlear implant manufacturer Advanced Bionics and the Food and Drug Administration last week took its toll on market leader Cochlear.
Mass spectrometry: Critical mass
26 July, 2002 by Melissa TrudingerDuring the past decade, dramatic progress in the field of mass spectrometry has resulted in a large increase in the number of commercially available mass spectrometry (MS) instruments principally used for biochemical analysis. Advances in mass spectrometry instrumentation, driven primarily by proteomics and the need to identify low abundance proteins (<50 femtomoles) has resulted in the current generation of instruments having approximately 50 times more sensitivity combined with substantially greater resolution than mass spectrometers available only four or five years ago.
Vision Bio chief spells out strategy
26 July, 2002 by Melissa TrudingerVision BioSystems' recent acquisition of British reagent company Novocastra Laboratories is part of a broader strategy to expand into the global diagnostic instruments market, according to managing director Michael Ohanessian.
Genera names new CEO
26 July, 2002 by Tanya HollisWalter and Eliza Hall Institute spin-out Genera Biosystems has appointed a new chief executive officer to spearhead partnership opportunities in the United States.
